SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Spyre Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$84.72+4.82 (+6.03%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Spyre Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Market Cap | $7.47B | $166.30M |
| Enterprise Value | $6.37B | $88.19M |
| PB Ratio | 6.78 | 2.03 |
| P/TBV Ratio | 6.78 | 2.29 |
Income (trailing twelve months)
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$201.34M | -$21.40M |
| Pretax Income | -$178.92M | -$14.34M |
| Net Income | -$178.92M | -$22.46M |
| EBITDA | -$201.34M | -$16.91M |
Returns
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -23.0% | -53.2% |
| Return on Assets (ROA) | -20.9% | -40.9% |
| Return on Capital Employed (ROCE) | -18.1% | -38.1% |
Balance sheet
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.10B | $61.43M |
| Net Cash (Debt) | $1.10B | $15.35M |
| Net Cash Per Share | $12.48 | $0.66 |
| Equity (Book Value) | $1.10B | $49.09M |
| Book Value Per Share | $12.49 | $1.37 |
| Tangible Book Value | $1.10B | $23.52M |
| Working Capital | $1.11B | $76.81M |
Financial position
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 18.53 | 3.34 |
| Quick Ratio | 17.38 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$208.94M | -$12.35M |
Efficiency
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.75M | -$703.34K |
| Employee Count | 102 | 74 |
Dividends and yields
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -2.40% | -23.3% |
Shares
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 88,173,800 | 58,127,000 |
| Shares Change (QoQ) | 11.7% | 0.54% |
| Float | 70,226,100 | 49,136,700 |
| Shares Held by Insiders | 20.4% | 11.6% |
| Shares Held by Institutions | 108.7% | 59.4% |
Taxes
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Spyre Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 61.47 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Spyre Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.